Vignette therapeutique de l'etudiant. Inhibiteur des SGLT 2 ou agoniste des récepteurs du GLP-1 chez un patient diabétique de type 2 avec maladie cardiovasculaire ?

Scheen, André; Paquot, Nicolas

Article (Scientific journals)

Scheen, André; Paquot, Nicolas

2018 • In Revue Médicale de Liège, 73 (1), p. 43-50

Peer reviewed

Permalink
https://hdl.handle.net/2268/221593

PubMed
29388411

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

rmlg201801_10.pdf

Publisher postprint (681.38 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

GLP; Heart failure; Liraglutide; Renal impairment; SGLT2 inhibitor; Type 2 diabetes; 1 receptor agonist; Empagliflozin

Abstract :

[en] Two classes of antidiabetic agents have shown a cardiovascular and renal protection in patients with type 2 diabetes and high cardiovascular risk. Empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, were granted a reduction of major cardiovascular events and mortality after the positive results of EMPA-REG OUTCOME and LEADER outcome trials, respectively. Protection mechanisms most probably differ between the two pharmacological classes and are perhaps complementary. The question that may arise in clinical practice is to know which drug should be selected between these two options in a patient with type 2 and established cardiovascular disease, before considering a potential combination. The aim of this article is to discuss about the best therapeutic choice according to the patient individual profile and the specificities of each molecule.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Paquot, Nicolas ; Université de Liège - ULiège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques

Language :

French

Title :

Vignette therapeutique de l'etudiant. Inhibiteur des SGLT 2 ou agoniste des récepteurs du GLP-1 chez un patient diabétique de type 2 avec maladie cardiovasculaire ?

Alternative titles :

[en] SGLT 2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?

Publication date :

2018

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

43-50

Peer reviewed :

Peer reviewed

Additional URL :

https://www.rmlg.ulg.ac.be

Available on ORBi :

since 26 March 2018

Statistics

Number of views

156 (2 by ULiège)

Number of downloads

125 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Scheen AJ, Radermecker RP, Philips JC, et al.-Recommandations européennes pour la prise en charge du diabéte, du pré-diabéte et des maladies cardio-vasculaires. 1ére partie : Gestion du diabéte et des facteurs de risque cardio-vasculaire. Rev Med Liege, 2013, 68, 585-592.
Scheen AJ, Charbonnel B.-Effects of glucoselowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. Diabetes Metab, 2014, 40, 176-185
Scheen AJ, Paquot N.-Actualisation 2015 des recommandations américaines et européennes pour le traitement du diabéte de type 2. Rev Med Liege, 2015, 70, 122-128.
Scheen AJ, Piérard L, Krzesinski J-M, et al.-Protection cardiovasculaire et rénale du patient diabétique de type 2 : le point aprés EMPA-REG OUTCOME et LEADER. Rev Med Liege, 2016, 71, 376-381.
Scheen AJ, Wallemacq C, Jandrain B, et al.-Protection cardiovasculaire du patient diabétique de type 2 : d'EMPA-REG OUTCOME à LEADER. Rev Med Suisse, 2016, 12, 1370-1375.
Zinman B, Wanner C, Lachin JM, et al.-Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015, 373, 2117-2128.
Scheen AJ.-EMPA-REG OUTCOME. L'empagliflozine réduit la mortalité chez le patient diabétique de type 2 à haut risque cardiovasculaire. Rev Med Liege, 2015, 70, 583-589.
Marso SP, Daniels GH, Brown-Frandsen K, et al.-Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016, 375, 311-322.
Scheen AJ.-Historique des Études cardiovasculaires : de l'UGDP . aux derniéres Études. Médecine des maladies Métaboliques, 2017, 11, 2S15-12S26.
American Diabetes Association.-Standards of medical care in diabetes -2017. Diabetes Care, 2017, 40, S1-S135.
Scheen AJ.-Cardiovascular outcome studies in type 2 diabetes : comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract, 2018, submitted.
DeFronzo RA.-Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab, 2017, 19, 1353-1362.
Fitchett D, Zinman B, Wanner C, et al.-Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J, 2016, 37, 1526-1534.
McMurray J.-EMPA-REG -the «diuretic hypothesis». J Diabetes Complications, 2016, 30, 3-4.
Heerspink HJ, Perkins BA, Fitchett DH, et al.-Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects. Potential mechanisms and clinical applications. Circulation, 2016, 134, 752-772.
Ponikowski P, Voors AA, Anker SD, et al.-2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2016, 37, 2129-2200.
Wanner C, Inzucchi SE, Lachin JM, et al.-Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med, 2016, 375, 323-334.
Scheen AJ, Paquot N.-Comment prescrire un médicament antidiabÉtique oral chez un patient diabÉtique de type 2 avec insuffisance rénale ? Rev Med Liege, 2017, 72, 462-468.
Scheen AJ.-SGLT2 inhibitors: benefit/risk balance. Curr Diab Rep, 2016, 16, 92.
Scheen AJ.-GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab, 2017, 43 Suppl 1, 2S13-12S19.
Mann JFE, Orsted DD, Brown-Frandsen K, et al.-Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med, 2017, 377, 839-848.
Scheen AJ.-GLP-1 receptor agonists and cardiovascular protection. Class effect or not ? Diabetes Metab, 2017, in press.
Bethel MA, Patel RA, Merrill P, et al.-Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis. Lancet Diabetes Endocrinol, 2017, Dec 5. pii: S2213-8587(17)30412-6. doi: 10.1016/ S2213-8587(17)30412-6. [Epub ahead of print].
Arnold SV, Inzucchi SE, Tang F, et al.-Realworld use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR(R) Research to Practice project. Eur J Prev Cardiol, 2017, 24, 1637-1645.
Scheen AJ.-Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet, 2015, 54, 1-21.
Davies MJ, Bain SC, Atkin SL, et al.-Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRARENAL): A randomized clinical trial. Diabetes Care, 2016, 39, 222-230.
Busch RS, Kane MP.-Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: A complementary approach to the treatment of type 2 diabetes. Postgrad Med, 2017, 129, 686-697.
Fadini GP, Bonora BM, Sarangdhar M, et al.-DPP-4 inhibitors moderate the risk of genitourinary tract infections associated with SGLT2 inhibitors. Diabetes Obes Metab, 2017, Oct 20. doi: 10.1111/ dom.13130. [Epub ahead of print].
Scheen AJ, Paquot N.-Metabolic effects of SGLT2 inhibitors beyond increased glucosuria : A review of clinical evidence. Diabetes Metab, 2014, 40, S4-S11.
Scheen AJ.-Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab, 2016, 42, 71-76.
Ussher JR, Drucker DJ.-Cardiovascular actions of incretin-based therapies. Circ Res, 2014, 114, 1788-1803.
Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.-EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents: implications for future treatment strategies in type 2 diabetes mellitus. Clin Ther, 2016, 38, 1288-1298.
Frias JP, Guja C, Hardy E, et al.-Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol, 2016, 4, 1004-1016.